Oragenics Launches New Professional and Consumer Commercial Websites
TAMPA, Fla.-- Oragenics, Inc. (NYSE:MKT - OGEN) today announced that it has launched two new websites. The first, www.evorapro.com, is designed to educate dental professionals about the benefits of oral probiotics in maintaining good oral health and balance, while also providing information on becoming a partner with Oragenics and offering its professional strength product, EvoraPro, in their practices.
The second, www.evoraoralprobiotics.com, features updated information on Oragenics’ consumer line of oral probiotics, EvoraPlus and EvoraPet, a simpler user interface and a more efficient shopping cart. All of the Evora products contain ProBiora3, Oragenics’ proprietary blend of three strains of bacteria specifically composed to naturally freshen breath, whiten teeth and support overall oral health and balance.
These new websites, along with a refresh of Oragenics’ current corporate site, www.oragenics.com, is part of the company’s ongoing efforts to enhance the quality and availability of information about its organization and products to dental professionals and consumers worldwide.
New content will continue to roll out on the websites over the coming months as more features are added to increase functionality.
“The websites are a critical facet of our outreach to the dental professional community and consumers,” said Dr. John N. Bonfiglio, President and CEO, Oragenics, Inc. “We are focusing our sales and marketing efforts on the dental professional and the consumers. These new websites will aid in the effort to provide the most useful information and highest quality products possible to our target audiences, and provide a pleasant shopping experience.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health for humans and pets. Oragenics has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation Inc., a synthetic biology company. The collaboration will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria. Oragenics also develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond March 31, 2014 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
Tel: 813-286-7900 x246
Chief Financial Officer
The Ruth Group
Stephanie Carrington/Aaron Estrada
Source: Oragenics, Inc.
Released May 2, 2013